Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)

NCT04183114 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

540

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Rubella Infection
Measles

Interventions

BIOLOGICAL: Measles-Rubella vaccine Bio Farma
BIOLOGICAL: MR Vaccine SII

Sponsor

PT Bio Farma